ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
Launched by IPSEN · Oct 23, 2014
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women ≥ 18-80 years.
- • Poststroke limb spasticity.
- • Patients who have suffered a stroke in the previous 6 months.
- • Treatment goal has been previously agreed with the patient or their legal representative.
- • Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation.
- • No previous treatment with BoNT-A.
- • Patient is able to follow the protocol.
- • Written informed consent.
- Exclusion Criteria:
- • Neuromuscular disease.
- • Use of drugs that interfere with neuromuscular transmission.
- • Any other condition that could interfere with rehabilitation or evaluation of the results.
- • Diagnosis of spasticity not associated with stroke.
- • Pregnant or nursing mothers.
- • Prior participation in any other study in the 6 months before study entry
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Palma De Mallorca, , Spain
Murcia, , Spain
Sevilla, , Spain
Salamanca, , Spain
Valladolid, , Spain
Cordoba, , Spain
Cadiz, , Spain
Granada, , Spain
Pontevedra, , Spain
Bilbao, , Spain
Lleida, , Spain
San Sebastián, , Spain
Huelva, , Spain
Santiago, , Spain
Barcelona, , Spain
Las Palmas De G.C., , Spain
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials